View Older Stories
-
Barclays Downgrades Insulet Corporation (PODD) to Underweight
-
Barclays Downgrades DexCom (DXCM) to Underweight
-
Morgan Stanley Reiterates Overweight Rating on DexCom (DXCM), 'Prelim Results Likely Clear the Bar'
-
Citi Opens 90-Day Upside Catalyst Watch on DexCom (DXCM)
-
Dexcom reports Q4 revenue of $1.26 billion, provides 2026 outlook
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
Goldman: 'Top Call Buying Opportunities for 2026'
-
BofA’s six MedTech picks for 2026 on strong earnings growth
-
Raymond James Reiterates Strong Buy Rating on Jabil (JBL)
-
DexCom (DXCM) PT Raised to $92 at Leerink Partners
-
Bernstein Shares Takeaways From the 5th Annual Diabetes Disruptor Conference
-
DexCom (DXCM) Added to Citi 90-Day Upside Catalyst Watch List
-
Evercore ISI Starts DexCom (DXCM) at In Line
-
Dexcom launches 15-day glucose monitor in US on Dec. 1
-
Dexcom receives FDA clearance for basal insulin dosing optimizer
-
'DexCom (DXCM) Too Cheap to Ignore'; Stock PT Lowered at Bernstein
-
This medtech stock is "objectively too cheap," BofA says
-
DexCom (DXCM) PT Lowered at Piper Sandler; 'We Strongly Recommend Investors Buy the Stock'
-
DexCom (DXCM) PT Lowered to $85 at BTIG
-
DexCom (DXCM) PT Lowered to $99 at Canaccord Genuity
-
DexCom (DXCM) Tops Q3 EPS by 4c ; Offers Guidance
-
DexCom (DXCM) call put ratio 3.2 calls to 1 put with a focus on October 31 weekly 75 and 80 calls
-
DexCom (DXCM) Mentioned Cautiously Again at Hunterbrook
-
TD Cowen on DexCom (DXCM): 'G7 Angst Has Created Attractive Risk/Reward Setup Into Q3 Print'
-
Piper Sandler Sees Good Setup for DexCom (DXCM) Stock, Recommends Purchase
-
Stifel Resumes DexCom (DXCM) at Buy
-
TD Cowen on DexCom (DXCM): ' G7 Issues Are Mostly Resolved, Limiting Share Shifts'
-
UBS Reiterates Buy Rating on DexCom (DXCM) Following Over 10% Selloff
-
DexCom (DXCM) Mentioned as short at Hunterbrook
-
DexCom (DXCM) options active on 24K contracts
-
DexCom CEO takes medical leave, COO named interim leader
-
Piper Sandler on calls with diabetes clinicians
-
Oppenheimer Downgrades DexCom (DXCM) to Perform
-
Piper Sandler on DexCom (DXCM): 'NIT2 Should More Than Offset; The Stock Should Be Owned Here'
-
DexCom (DXCM) Shares Active, Conf. Ongoing
-
Argus Starts DexCom (DXCM) at Buy
-
DexCom (DXCM) PT Raised to $106 at UBS
-
DexCom (DXCM) Tops Q2 EPS by 3c; offers guidance
-
DexCom adds AI meal logging to Stelo and G7 glucose monitors
-
Dexcom (DXCM) Removes Certain Dexcom G6, G7, ONE, and ONE+ Receivers Due to Speaker Malfunction
-
BTIG names top large-cap picks for second half of 2025
-
Oppenheimer Reiterates Outperform Rating on DexCom (DXCM)
-
DexCom (DXCM) Gains Amid Chatter of HHS Push for Wearable Tech
-
Piper Sandler's Key MedTech Takeaways From ADA 2025
-
Truist Securities Starts DexCom (DXCM) at Buy
-
Piper Sandler Highlights DexCom (DXCM) Stock Following Educator Survey
-
Goldman Sachs Starts DexCom (DXCM) at Buy
-
RBC Capital on DexCom (DXCM): 'Valuation Signals Opportunity'
-
DexCom (DXCM) Appoints Jacob S. Leach as COO
-
DexCom (DXCM) PT Raised to $106 at Canaccord Genuity

